NCT03382522View on ClinicalTrials.gov

Prognostic Value of SPECT-CT Quantitative Indices for the Response Assessment of Bone Metastatic Prostate Carcinoma

CompletedOBSERVATIONAL
Enrollment

19

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

March 30, 2018

Study Completion Date

March 30, 2018

Conditions
Prostate Cancer
Trial Locations (1)

29609

CHRU de Brest, Brest

All Listed Sponsors
lead

University Hospital, Brest

OTHER

NCT03382522 - Prognostic Value of SPECT-CT Quantitative Indices for the Response Assessment of Bone Metastatic Prostate Carcinoma | Biotech Hunter | Biotech Hunter